Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orphan Australia has received registration approval from the Therapeutic Goods Administration for DepoDur, a morphine formulation, in Australia.
Subscribe to our email newsletter
DepoDur, which was developed by and licensed from Pacira Pharmaceuticals, utilizes Pacira’s DepoFoam technology and is a novel, single dose modified-release formulation of morphine.
The approved indication in Australia is for the relief of post-operative pain, following major orthopedic, abdominal or pelvic surgery via the lumbar epidural route, without the restrictions and potential complications associated with an indwelling epidural catheter, at a maximum recommended dose of 10mg.
DepoDur will be available in Australia from February 2008.